focus -WSS

focus

author：hotspot 2025-09-06 07:58:25 - browse：653

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： What we owe ALS patients — and why one company fell short

WSS

RSV injection headlines need to be accurate for good uptake

Scientists grapple with ethics of stem cell research

Will an HIV vaccine ever be a reality?

Dementia risk linked to living in disadvantaged areas: Study

Are infertility treatments 'essential' during the Covid

Study points to new risk in gene therapy death of Terry Horgan

Wikipedia

focus

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Sanders wants to replace patents with prizes for drug inventions

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Drug repurposing or repositioning? The language matters

CRISPR base editing slashes cholesterol levels in monkeys

Peter Hotez and the public health issue of online harassment

WHO recommends second malaria vaccine

Tori Bowie and the unacceptable rates of Black maternal death

Some top drug companies are starting to take action on climate

focus

Experts study whether long Covid risk adds up with each reinfection

IVG is promising — but it won’t replace IVF quite yet

Jan. 6 charges against Trump would add to his mounting legal peril as he campaigns for 2024

Some top drug companies are starting to take action on climate

IVG is promising — but it won’t replace IVF quite yet

Health insurers' Q3 question: how much care are people getting?

entertainment

hotspot

entertainment

focus